Sebastian Aguiar, geroscientist and Venture Fellow at Apollo Ventures, delivers the Lord Florey Lecture at Lincoln College, Oxford in November 2018. H...
What’s new in media and industry: Who’s who in longevity, and more
Here’s our handpicked selection of the best interviews, blog posts, popular articles, and breaking biotech news of the last two weeks: Want a systemat...
Glucosamine: The new metformin? | Interview with Dr. Michael Ristow (part ii)
Last week when we heard from Dr. Ristow, he turned the outdated notion of the “free radical theory of aging” on its head, and demonstrated that antiox...
What’s new in media and industry: Huge piles of money, and more
Here’s our handpicked selection of the best blog posts, popular articles, and breaking biotech news of the last two weeks: Longevity enthusiasts...
This chip can pluck the bad apples out of your blood
Many years from now, you’re reclining in one of the many gray-blue armchairs that line the walls of a clinic. Your arm is propped up on a collapsible ...
James Peyer: Where are stem cell therapies headed?
Someday soon we may be able to replace tissues or entire organs with those grown from a patients’ own stem cells… but just how soon? What ...
Will this protein help speed up clinical trials?
Biomarkers are a big deal in the clinical world: if as a doctor you’re able to take one simple measurement that allows you to look into a patient’s fu...
James Peyer: Why primary indications matter
“Aging” isn’t a disease as recognized by the FDA–not yet anyway. But then how will the companies trialing anti-aging drugs eve...
James Peyer: Navigating the “Biotech Valley of Death”
Ever hear about an exciting discovery in the biomedical world, then later wonder why it seemingly dropped off the face of the Earth? In fact, it’...
James Peyer: “The 21st century will be defined by our struggle against the diseases of aging.”
“At what age would you like to get Alzheimer’s?” This was the question posed by venture capitalist, former stem cell biologist and G...